Today, the 25th China Equity Investment Series Rankings, initiated by the Zero2IPO Research Center under Zero2IPO Holdings, were officially announced. Efung Capital has been named to the Top 30 Chinese Healthcare Investment Institutions list for multiple consecutive years!
Since 2001, Zero2IPO Research Center has been publishing annual rankings of China's equity investment industry for 24 consecutive years. Adhering to rigorous scientific research methodologies and a fair, impartial ranking approach, these rankings aim to provide a sound evaluation and benchmarking system for China's equity investment industry. The 2025 VC/PE comprehensive rankings include four main categories—Early-Stage Investment Institutions, VC Institutions, PE Institutions, and State-Owned Investment Institutions—along with Strategic Investor rankings, M&A Investment Institution rankings, "Specialized and Sophisticated" (SRDI) Investment Institution rankings, and Boutique Investment Institution rankings.
Innovation-Driven, Efung Steadfast
Looking back at 2025, China's equity investment market moved forward steadily amid interwoven opportunities and challenges. On one hand, waves of technological innovation continued to drive profound industrial transformation, with sectors such as artificial intelligence, advanced manufacturing, semiconductors, and innovative drugs bursting with vitality. More long-term capital entered the market successively, driven by policy support, with "investing early, investing small, investing long, investing hard" becoming a new industry consensus, signaling market recovery. On the other hand, structural adjustments within the industry are still ongoing, with fundraising, investment, and exit challenges placing higher demands on investment institutions' industry analysis capabilities, post-investment service efficiency, and resilience to navigate market cycles. Against this dual backdrop, institutions that can accurately identify trends, deeply empower portfolio companies, and achieve sustainable returns have seen their core value become increasingly prominent.
Looking ahead, Efung Capital will remain steadfast as a "guardian" of the hard-tech wave and a "catalyst" for new quality productive forces. With long-term capital and professional services, Efung will accompany China's innovation-driven enterprises through industry cycles, collectively creating health-oriented value for the future.